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ABSTRACT
Background Antiplatelet agents reduce recurrence after 
cerebral ischaemia but are not effective in all patients, in 
part because of treatment resistance. The primary aim was 
to assess the proportion of patients who are insensitive 
to clopidogrel. The secondary aim was to assess the 
association between insensitivity to clopidogrel and 
recurrent cerebrovascular events.
Methods Following written informed consent, independent 
patients with a recent non- cardioembolic ischaemic stroke 
or transient ischaemic attack, and taking clopidogrel, 
were enrolled. Platelet function was assessed with remote 
measurement of surface expression of P- selectin (CD62P) 
using commercial kits sensitive to aspirin or clopidogrel. 
Participants’ general practitioners provided details on 
recurrent vascular events at least 90 days later. Data are 
mean (SD) and median [IQR]. Resistance was defined as: 
aspirin median fluorescence (MF) >500 units, clopidogrel 
MF >860 units. Non- parametric descriptors and tests were 
used.
Results 63 patients were recruited: mean age 64 (13.7) 
years, women 47%. At baseline, 59 (95%) patients 
were taking clopidogrel alone with 3 (5%) on combined 
clopidogrel and aspirin. Assessment of platelet surface 
P- selectin revealed: aspirin test 528 [317, 834], >500 
54.8%; clopidogrel test 429 [303, 656], >860 11.3%. No 
participants on aspirin and clopidogrel showed aspirin 
resistance. Thirteen (20.6%) patients had a recurrent 
cerebrovascular event; those with an ischaemic stroke 
had a non- significantly higher baseline P- selectin using 
the clopidogrel test as compared with those with no 
recurrence: 626 [380, 801] versus 406 [265, 609], p=0.08.
Conclusions Remote measurement of platelet function 
assessed using the platelet surface expression of P- 
selectin is feasible. 11% of patients taking clopidogrel 
showed resistance. No significant associations were noted 
between clopidogrel resistance and recurrent ischaemic 
events.
INTRODUCTION
Antiplatelet drugs are effective at reducing 
recurrent events after ischaemic stroke or tran-
sient ischaemic attack (TIA).1–6 Unlike other 
secondary prevention interventions such as 
blood pressure and lipid lowering, antithrom-
botic antiplatelet agents are prescribed and 
administered without ongoing monitoring 
as there are no widely available, affordable, 
effective and validated tests of platelet func-
tion. Despite this, over a third of patients in 
some cohorts are insensitive to the antiplatelet 
effects of clopidogrel7 8; a smaller proportion of 
patients appear to be resistant to aspirin.8 9
Surface platelet expression of P- selectin 
(CD62P) correlates with other platelet function 
measures and can be tested remotely from the 
patient,10 in contrast to other techniques that 
cannot be used remotely.11 12 Antiplatelet resis-
tance has been defined for aspirin as median 
fluorescence (MF) >500 units, and for clopido-
grel MF >860 units in separate studies assessing 
acute coronary syndrome,13 and ischaemic 
stroke and patients with TIA, respectively.14 In 
a substudy of the large Triple Antiplatelets for 
Reducing Dependency after Ischaemic Stroke 
(TARDIS) trial, remote assessment of P- selectin 
was feasible and found that aspirin and clopi-
dogrel reduced stimulated P- selectin although 
25% of patients on clopidogrel had high 
on- treatment platelet activity.14
We assessed the proportion of patients 
with a history of cerebral ischaemia who were 
insensitive to clopidogrel and the association 
with recurrent ischaemic or bleeding events. 
Our primary aim was to assess the proportion 
of patients who are insensitive to clopidogrel. 
The secondary aim was to assess the association 




Independent adults (modified Rankin Scale, 
mRS≤3) aged ≥40 years at high risk of recur-
rent ischaemic stroke or TIA were eligible for 
recruitment if they had a clinical diagnosis 
of ischaemic non- cardioembolic stroke or 
TIA, were on clopidogrel for at least 5 days 
prior to recruitment and were able to provide 
written informed consent. Patients on antico-
agulation (eg, warfarin, direct oral anticoagu-
lants, heparin) were excluded. Patients were 
recruited from the stroke service (inpatient or 
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outpatient) at Nottingham University Hospitals NHS Trust. 
Participants were asked to complete a short questionnaire 
and underwent a blood test on the day of recruitment. We 
aimed to recruit 60 patients to assess the proportion of 
patients resistant to clopidogrel. The study was not powered 
to assess the association between P- selectin clopidogrel test 
values and clinical outcomes. The investigator- initiated 
study was funded by Platelet Solutions (Nottingham, UK) 
and Innovate UK SMART award, and sponsored by the 
University of Nottingham.
P-selectin assay
P- selectin is derived from alpha- granules within platelets and 
becomes exposed on the platelet surface membrane when 
platelets are activated. Measurement of surface expression 
of P- selectin was performed using commercial kits sensi-
tive to aspirin or clopidogrel (Platelet Solutions). Citrate 
anticoagulated blood was kept at 37°C once collected using 
a dry heat pad and insulation pouch, then incubated with 
platelet stimulants: arachidonic acid 0.5 mM for aspirin 
testing; ADP 10 µM for clopidogrel testing; and an unstimu-
lated sample for baseline expression. After 5 min of incuba-
tion, a fixative (PAMFix)15 was added and the fixed samples 
were transferred to the Nottingham flow cytometry labora-
tory for processing. Fixed blood was incubated with fluores-
cent antibodies to identify platelets (CD61) and P- selectin 
(CD62P). MF was recorded for platelet surface expression 
of P- selectin for each sample.
Clinical outcomes
A questionnaire was completed by participants on recruit-
ment detailing any history of bleeding while on anti-
platelet medication. Participants’ general practitioners 
(GP) were contacted at least 90 days later to record any 
Table 1 Baseline characteristics of participants
All Clopidogrel only Aspirin+clopidogrel P value
n (%) 62 (100.0) 59 (95.2) 3 (4.8)
Male (%) 33 (53.2) 33 (55.9) 0 0.058
Age, years 63.7 (13.7) 63.0 (13.5) 78.0 (8.9) 0.06
Preindex event
  Stroke (%) 9 (14.5) 8 (13.6) 1 (33.3) 0.34
  TIA (%) 8 (12.9) 6 (10.2) 2 (66.7) 0.004
  IHD (%) 6 (9.7) 5 (8.5) 1 (33.3) 0.16
  Diabetes (%) 11 (17.7) 10 (16.9) 1 (33.3) 0.47
  Smoking (%) 9 (14.5) 9 (15.3) 0 0.74
Index event
  Ischaemic stroke (%) 44 (71.0) 42 (71.2) 2 (66.7) 0.87
  TIA (%) 18 (29.0) 17 (28.8) 1 (33.3) 0.87
  Thrombolysis (%) 4 (6.5) 4 (6.8) 0 0.64
  Length of stay, days 1 [1,3] (0–60) 1 [0,3] (0–60) 2 [−] (1-7) 0.25
At recruitment
  Time from index event, days 49 [35,75] (1–285) 52 [36,76] (1–285) 1 [−] (1–22) 0.006
  mRS 0 [0,1] 0 [0,1] 0 [−] 0.89
  On clopidogrel (%) 62 (100) 59 (100) 3 (100) –
  Time on clopidogrel, days 50 [35, 76] (8–1878) 48 [35, 69] (8–1878) 313 [−] (8–962) 0.41
  On aspirin (%) 3 (4.8) 0 3 (100) –
  Treated hypertension (%) 43 (69.4) 40 (67.8) 3 (100) 0.24
  Treated hypercholesterolaemia (%) 59 (95.2) 56 (94.9) 3 (100) 0.69
  Proton pump inhibitor (%) 19 (30.6) 17 (28.8) 2 (66.7) 0.17
  Systolic BP, mm Hg 135.7 (19.5) 134.9 (19.3) 150.0 (22.5) 0.21
  Diastolic BP, mm Hg 76.3 (13.5) 76.6 (13.7) 71.7 (7.8) 0.26
Bleeding history on antiplatelet(s)
  Minor bleeding (%) 17 (27.4) 17 (28.8) 0 0.28
  Major bleeding (%) 0 0 0 –
Data are number (%), mean (SD), median [IQR], (min–max); comparison between clopidogrel versus aspirin+clopidogrel groups by χ2 
test, Kruskal- Wallis test or one- way analysis of variance.
Sixty- three participants recruited but 1 had no data collected.
BP, blood pressure; IHD, ischaemic heart disease; mRS, modified Rankin Scale; TIA, transient ischaemic attack.
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recurrent vascular events and confirmed with admitting 
hospital records where available. An additional follow- up 
telephone call at least 90 days following recruitment was 
performed in a subset of patients who provided sepa-
rate written informed consent. Clinical outcomes were 
recorded, including: functional status (mRS); disability 
(Barthel Index); quality of life (European Quality of 
Life Visual Analogue Scale); cognition (telephone Mini- 
Mental State Examination), Modified Telephone Inter-
view for Cognition Scale, verbal fluency); and mood 
(Zung Depression Scale).
Statistics
Resistance was defined prospectively using cut- offs previ-
ously utilised in stroke patients in a large randomised 
controlled trial: aspirin MF >500 units, clopidogrel MF 
>860 units.14 Data are number (%), mean (SD) and 
median [IQR]. Baseline differences in groups based on 
antiplatelet therapy were assessed using analysis of vari-
ance for continuous variables or χ2 for categorical varia-
bles. Non- parametric descriptors and tests were used with 
significance set at p<0.05. Correlations between baseline 
P- selectin clopidogrel test values and clinical outcomes 
were assessed using Spearman correlation with resultant 
‘r’ and 2- sided p values. Analyses were performed using 
SPSS V.24.
Data availability
Data pertaining to this paper are available from the corre-
sponding author on reasonable request.
RESULTS
Sixty- three patients were recruited although one had no 
data or blood collected. Of the remaining 62 participants, 
53% were men with an average age of 64 years (table 1). 
The index event was stroke in 44 (71%) participants and 
TIA in the remaining 29%. All participants were on clopi-
dogrel 75 mg daily and three were also on aspirin 75 mg 
daily at the time of recruitment. Participants on dual anti-
platelets tended to have a prior history of TIA reflecting 
the results of the Clopidogrel in High- Risk Patients with 
Acute Nondisabling Cerebrovascular Events (CHANCE) 
trial.4 Time from index event to recruitment was longer in 
those on clopidogrel only versus aspirin and clopidogrel. 
Seventeen (27%) participants had a history of minor 
Table 2 P- selectin in response to arachidonic acid (AA, aspirin test) and ADP (clopidogrel test)
All Clopidogrel only Aspirin +clopidogrel P value
AA MF
  Number (%) 62 (100) 59 (95.2) 3 (4.8) –
  Mean (SD) 590 (330) 612 (323) 160 (118) 0.020
  Median [IQR] 528 [317, 834] 547 [375,851] 103 [−] 0.013
  >500 (%) 34 (54.8) 34 (57.6) 0 0.050
ADP MF
  Number (%) 62 (100) 59 (95.2) 3 (4.8) –
  Mean (SD) 493 (266) 498 (269) 392 (202) 0.51
  Median [IQR] 429 [303, 656] 425 [307, 656] 502 [−] 0.54
  >860 (%) 7 (11.3) 7 (11.9) 0 0.53
Data are number (%), median [IQR] or mean (SD); comparisons by χ2 test, Kruskal- Wallis test or one- way analysis of variance.
MF, median fluorescence.
Figure 1 P- selectin surface expression in response to 
arachidonic acid. MF, median fluorescence.
Figure 2 P- selectin surface expression in response to ADP. 
MF, median fluorescence.
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bleeding on clopidogrel, with the remainder reporting 
no history of bleeding (table 1).
Assessment of platelet surface P- selectin in 62 partici-
pants revealed (table 2): aspirin test 528 [317, 834], >500 
54.8%, figure 1; clopidogrel test 429 [303, 656], >860 
11.3%, figure 2. Thus, 11.3% of participants had evidence 
of resistance to clopidogrel. No participants on aspirin 
and clopidogrel showed aspirin resistance. P- selectin 
levels for the clopidogrel test did not differ between 
patients taking and not taking a proton pump inhibitor 
(PPI 554 [307, 729] vs no PPI 406 [289, 626] (p=0.32)) or 
between patients with and without a history of bleeding 
(aspirin test: bleeding 691 [438,791] vs no bleeding 495 
[296, 870], p=0.28; clopidogrel test: 444 [321, 685] vs 
425 [285, 656], p=0.88) (table 3). No patients with minor 
bleeding were resistant to clopidogrel (clopidogrel test 
>860), while 7 (15.6%) patients with no bleeding symp-
toms were resistant to clopidogrel.
GP follow- up data were available for all participants. 
Thirteen (20.6%) participants had a recurrent vascular 
event during the follow- up period: nine ischaemic strokes 
and four TIAs. No participants died or had acute coronary 
syndromes during the follow- up period. Baseline P- se-
lectin clopidogrel test levels were non- significantly higher 
in those participants that had a recurrent ischaemic stroke 
as compared with those without recurrence (626 [380, 
801] vs 406 [265, 609], p=0.08). Only one participant 
with recurrent ischaemic stroke had baseline P- selectin 
clopidogrel test >860 suggestive of clopidogrel resistance. 
When pooled together, those with either a recurrent isch-
aemic stroke or TIA had non- significantly higher baseline 
P- selectin clopidogrel test levels compared with those with 
no recurrence (581 [328, 752] vs 406 [239, 609], p=0.15). 
Only 1/13 (7.7%) participant with recurrent ischaemic 
stroke or TIA had a baseline P- selectin clopidogrel test 
>860 as compared with 6/49 (12.2%) participants with 
no recurrence (p=0.65). There was no statistically signif-
icant correlation between baseline P- selectin clopidogrel 
test levels and recurrent cerebrovascular events using an 
ordinal scale where no event=0, TIA=1 and ischaemic 
stroke=2 (r=0.200, p=0.12).
Telephone follow- up data were only available for 19 
(30.2%) participants. No statistically significant correla-
tions were noted between baseline P- selectin clopidogrel 
test levels and clinical outcomes (table 4).
DISCUSSION
In this single centre study, remote measurement of 
platelet function assessed using the platelet surface 
expression of P- selectin was feasible. Over a tenth of 
patients taking clopidogrel showed resistance. There 
were non- significantly higher baseline P- selectin clopi-
dogrel test levels in those participants who had a recur-
rent cerebral ischaemic event as compared with those 
with no recurrence.
The proportion of patients demonstrated to be resis-
tant to clopidogrel varies in the literature but may 
exceed 35%.16 A variety of platelet function tests have 
been reported, but the majority need to be performed 
Table 3 P- selectin in response to arachidonic acid (AA, aspirin test) and ADP (clopidogrel test) by minor or no bleeding
All Minor bleeding No bleeding P value
AA MF
  Number (%) 62 (100) 17 (27.4) 45 (72.6) –
  Mean (SD) 590 (330) 644 (280) 569 (348) 0.43
  Median [IQR] 528 [317, 834] 691 [438, 791] 495 [296, 870] 0.28
  >500 (%) 34 (54.8) 12 (70.6) 22 (48.9) 0.13
ADP MF
  Number (%) 62 (100) 17 (27.4) 45 (72.6) –
  Mean (SD) 493 (266) 481 (213) 498 (286) 0.83
  Median [IQR] 429 [303, 656] 444 [321, 685] 425 [285, 656] 0.88
  >860 (%) 7 (11.3) 0 7 (15.6) 0.08
Data are number (%), median [IQR] or mean (SD); comparisons by χ2 test, Kruskal- Wallis test or one- way analysis of variance.
MF, median fluorescence.
Table 4 Correlations between baseline P- selectin 
clopidogrel test and clinical outcomes after day 90
r P value
Number (%) 19 (30.2) –
mRS 0.164 0.50
Barthel index −0.208 0.39
EQ- VAS 0.075 0.76
t- MMSE −0.060 0.81
TICS- M −0.231 0.34
Verbal fluency −0.235 0.33
Zung −0.125 0.61
Data are number (%), r with two- sided p values using Spearman 
correlation.
EQ- VAS, European Quality of Life Visual Analogue Scale; mRS, 
modified Rankin Scale; TICS- M, Modified Telephone Interview 
for Cognition Scale; t- MMSE, telephone Mini- Mental State 
Examination.
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in a timely manner close to the patient. In comparison, 
platelet surface expression of P- selectin provides unique 
remote assessment of platelet function distal to the patient 
and has been shown to be feasible in healthy volunteers 
as well as patients with acute coronary syndrome, surgery 
and mild bleeding disorders.16 Furthermore, storage and 
transportation of the fixed samples to a core laboratory 
for analysis were feasible across multiple hospital sites as 
part of a large clinical trial of stroke and TIA patients.14 
This analysis demonstrated that 24.7% of 97 patients on 
clopidogrel at baseline demonstrated clopidogrel resis-
tance defined as MF >860,14 a higher proportion than in 
the present study.
In patients with acute coronary syndrome, clopidogrel 
resistance (demonstrated using platelet surface P- selec-
tion expression) has been shown to be associated with 
an increased risk of cardiovascular death, acute coronary 
syndrome or stent thrombosis.13 The present study is the 
first to assess the association between baseline platelet 
surface expression of P- selectin indicative of clopidogrel 
resistance in patients with prior ischaemic stroke or TIA 
and recurrent cerebrovascular events. Although there was 
no association when using predefined cut points, median 
P- selectin clopidogrel test values were non- significantly 
higher in those with a recurrent vascular event than in 
those without. This finding needs to be replicated in 
larger datasets, but is in line with another study using 
thromboelastography ADP maximum amplitude as a 
marker of high on- treatment platelet reactivity, which 
was associated with a higher risk of recurrent ischaemic 
events at 90 days.17 However, there is an absence of trials 
assessing whether adjusting antiplatelet therapy post 
stroke in patients with clopidogrel resistance is feasible, 
safe and efficacious at reducing recurrent cerebrovas-
cular events. Such adjustment might comprise switching 
from clopidogrel to aspirin, using combined aspirin and 
clopidogrel,4 5 or using combined aspirin and dipyrida-
mole.6 18 19 In this respect, it is interesting to note in the 
present study that all patients on combined aspirin and 
clopidogrel had suppressed P- selectin expression with 
both of the aspirin and clopidogrel tests.
The strength of this study is its generalisability to clin-
ical practice and further demonstration that platelet func-
tion can be assessed remotely after stroke, in this case in 
a predominantly outpatient population. However, there 
are several limitations. First, the study was small and this 
limited statistical power to assess the relationship between 
P- selectin expression and clinical outcome. This is particu-
larly relevant for the binary comparison of non- supressed 
P- selectin versus stroke recurrence. Further, participants 
were assessed around 7 weeks after their index event and 
so at a time when the risk of recurrence was likely to be 
low. Second, as a predominantly outpatient population, 
the participants tended to have a mild stroke or TIA and 
so the results cannot be extrapolated to a more severe 
population. Third, we did not collect the time when anti-
platelet medication was last taken and so were unable to 
assess whether the time from medication taken to blood 
testing impacting on the results. Last, we cannot rule out 
that some participants were non- compliant with their 
antiplatelet therapy.
In summary, we add to the growing body of evidence 
that remote assessment of platelet function using P- se-
lectin is feasible and of potential benefit to patient 
management. Just over a tenth of patients were resistant to 
clopidogrel. Although there was a non- significant associa-
tion with recurrent cerebrovascular events in those resis-
tant to clopidogrel, the study was not powered to answer 
this definitively. Therefore, further studies are needed to 
establish whether platelet function testing can be used to 
guide antiplatelet therapy in patients who appear to be 
resistant to clopidogrel.
Twitter Jason Philip Appleton @JPAppleton
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